---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-078072"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:46:22.190642+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics approved to transfer stock listing from Nasdaq Global Select to Capital Market on July 6

## Summary
- Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.
- Transfer becomes effective at the opening of business on July 6, 2023.
- Aprea's common stock (APRE) will continue trading on the Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-23-078072
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/0001104659-23-078072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465923078072/tm2320610d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-078072
- JSON: https://secwatch.observer/filing/0001104659-23-078072.json
- Plain text: https://secwatch.observer/filing/0001104659-23-078072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.